Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C: Real-life Data

Ad dress for Cor res pon den ce: Zehra Karacaer MD, Gülhane Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey Phone: +90

n: Number, PROD: Paritaprevir-ritonavir-ombitasvir-dasabuvir combination, L/S: Ledipasvir-sofosbuvir combination, SD: Standard deviation, ASEX: Arizona Sexual Experiences

In this study, we investigated the prevalence of mixed genotype chronic HCV infection, risk factors related to mode of transmission, and outcomes of DAA therapy in these

In the RUBY-1 study, stage 4 and 5 CKD patients infected with non-cirrhotic genotype 1 were treated with PrOD for 12 weeks, and SVR12 was achieved at a rate of 90%.. In the light

Paritaprevir/Ritonavir/Ombitasvir plus dasabuvir regimen in the treatment of genotype 1 chronic hepatitis C infection in patients with severe renal impairment and end-stage

Results: Hsa-miRNA-21-3p and hsa-miRNA-122-3p levels increased 3-4 fold in patients without HCV related LC (HCV-LC) and hsa- miRNA-29a-3p expression in HCV infected patients

In the current study, we performed an analysis to examine the association between the SNP in the promoter region of TNF-α-308 rs3091256 and fibrosis score, ALT level,

To study level of vitamin D in Egyptian patients with chronic HCV infection and to investigate its correlation with activity and fibrosis scores of their liver biopsies, as well